Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

Exclusion Criteria

• •Have a known sensitivity or allergy to the class of medication of the active ingredient in the study medication or any of the study medication's components;
• •Have any intraocular inflammation (e.g., white blood cells or flare) present in the study eye at the Visit 1slit lamp examination;
• •Have a score greater than "0" on the Ocular Pain Assessment at Visit 1 or 2 in the study eye;
• •Have an immunosuppressive or an autoimmune disease that in the opinion of the Investigator could affect intraocular inflammation or the normal healing process of the eye;
• •Have active or chronic/recurrent ocular or systemic disease that is uncontrolled and will likely affect wound healing;
• •Currently have suspected or known malignancy or be currently receiving antineoplastic therapy;
• •Be a female who is currently pregnant, planning a pregnancy, lactating, not using a medically acceptable form of birth control throughout the study duration, or have a positive urine pregnancy test at Visit 1;
• •Use anti-inflammatory agents, analgesics/pain relievers (including opioids, narcotics and other pain medications) or immunomodulating agents, systemically, or in either eye, and/or use medications for benign prostatic hyperplasia (BPH), from the washout period through the duration of the study